✨ Free AI Report
ALK-Abelló A/S: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research ALK-Abelló A/S
Company Research

ALK-Abelló A/S: Business Overview, Financials & Competitive Analysis

ALK-Abelló is a Denmark-based pharmaceutical company specializing in allergy immunotherapy products and is one of the world's largest makers of allergy immunotherapy products, with 67% of revenue from European sales. ...

Analyst-debate audio for ALK-Abelló A/S

AskCyborg analysts argue the bull and bear cases for ALK-Abelló A/S across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
7/ 10Strong

Cyborg Score thesis

Dominant player in allergy immunotherapy with expanding product portfolio and emerging anaphylaxis solutions targeting a growing...

Read the full analyst-debate transcript →
Industry Specialty Pharmaceuticals - Allergy Immunotherapy
3 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: November 2, 2026
AI-Generated Research
30+ Page Report

Get the Latest ALK-Abelló A/S Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

ALK-Abelló A/S Overview

Pro stress-test →

ALK-Abelló is a Denmark-based pharmaceutical company specializing in allergy immunotherapy products and is one of the world's largest makers of allergy immunotherapy products, with 67% of revenue from European sales. The company develops, produces, and markets allergy immunotherapy and anaphylaxis treatments.

Strategic Profile

Pro stress-test →

ALK is the world leader in allergy immunotherapy, providing products as injections, sublingual drops and sublingual tablets. The company offers a digital ecosystem platform connecting allergy sufferers with diagnostic solutions and emergency treatments for anaphylaxis.

Competitive Landscape

Pro stress-test →

ALK holds the leading market position in allergy immunotherapy globally. Primary competition comes from pharmaceutical companies developing alternative allergy treatments and immunotherapy approaches. The company maintains strategic partnership with Torii Pharmaceutical for regional product development including GRAZAX, CEDARCURE, and MITICURE.

Industry Context

ALK-Abelló A/S operates in Specialty Pharmaceuticals - Allergy Immunotherapy.

Key facts

Founded: 1923 · Headquarters: Horsholm, Denmark · Employees: 2900 · Revenue: N/A · Market cap: N/A

What the AI analysts debated

AI-generated and not independently verified: selected findings from the multi-agent debate on ALK-Abelló A/S.

  • Received positive recommendation for EURneffy 1 mg, a needle-free anaphylaxis treatment for children (January 2026)
  • Company strategy focuses on sublingual immunotherapy tablets for grass pollen, ragweed, and house dust mite allergies
+2 more AI-generated counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • February 2026Annual report 2025 presentation scheduled
  • January 2026EURneffy needle-free anaphylaxis treatment receives positive regulatory recommendation
  • +1 moreTrack every material event for ALK-Abelló A/S as it happens. Explore monitoring →
Get alerted when ALK-Abelló A/S has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Kytopen/Oral ImmunotherapyEuropean allergy immunotherapy competitor→ASIT biotech PlatformImmunotherapy innovation for allergies→Torii Collaboration ProductsRegional immunotherapy partnership→

Compare ALK-Abelló A/S with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

ALK-Abelló A/S operates in Specialty Pharmaceuticals - Allergy Immunotherapy. See how the rest of the sector scores on the Cyborg framework.

Browse Specialty Pharmaceuticals - Allergy Immunotherapy research →
NEW · MCP server

Ask your AI assistant about ALK-Abelló A/S

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare ALK-Abelló A/S and its top competitor on Cyborg Score”
“What did ALK-Abelló A/S do this quarter?”
“Is ALK-Abelló A/S a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg research is made

⚔

AI analyst debate, not single-author opinion

Every report is generated by a panel of AI analysts arguing across 11 dimensions, so counter-arguments sit alongside the case. The debate is a reasoning process; it does not independently verify facts.

📊

Dated, not live

The Cyborg Score and recent developments reflect public sources as of the date shown and can miss or lag recent events. Check primary sources before relying on them.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The Cyborg Score is an AI-generated opinion under that framework, not a credit rating or an investment recommendation.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, and news flow, analysed by AI models. Read the methodology →

AI-generated research summary based on public sources; it may contain errors or omissions. Not investment advice. Not reviewed or endorsed by the companies covered. Report an error: legal@askcyborg.com (you must copy support@askcyborg.com) · Terms of Service

Frequently asked questions

What does ALK-Abelló A/S do?+
ALK-Abelló is a Denmark-based pharmaceutical company specializing in allergy immunotherapy products and is one of the world's largest makers of allergy immunotherapy products, with 67% of revenue from European sales. ...
What is ALK-Abelló A/S's Cyborg Score?+
ALK-Abelló A/S has a Cyborg Score of 7/10 (Strong). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are ALK-Abelló A/S's main competitors?+
Named competitors include Kytopen/Oral Immunotherapy, ASIT biotech Platform, Torii Collaboration Products. The full competitive landscape is in the AskCyborg report.
How can I get the full ALK-Abelló A/S research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the ALK-Abelló A/S research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track ALK-Abelló A/S over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

More Specialty Pharmaceuticals - Allergy Immunotherapy research

Companies in the same sector and named competitors, ranked by Cyborg Score.

7ALK-Abelló A/S